Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$2.24 ▼ -0.01
(-0.44%)
MKT CAP: $332.1M • VOL: 1.46M
52W L $1 52W H $3
ALEC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $21.0M | $100.6M | $97.1M |
| YoY Revenue Growth % | -79.1% | +3.6% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$156.0M | -$145.0M | -$151.7M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$143.0M | -$119.0M | -$130.0M |
| EBITDA (Normalized) | -$156.0M | -$144.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$184.0M | -$229.9M | -$184.2M |
| Capital Expenditures (CapEx) | $41.0K | $1.3M | — |
| Free Cash Flow (FCF) | -$184.1M | -$231.2M | -$184.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $65.8M | $33.0M | — |
| Total Debt (Short + Long Term) | $9.3M | $9.4M | — |
| Total Stockholders' Equity | $30.6M | $126.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ALEC.